Children with a Common Genetic Variant May Have More Inflammation in Response to an Asthma Drug

Asthma Biologic Interacts with Common Genetic Variant in Children

The frequently used biologic drug mepolizumab may cause an exaggerated inflammatory response in children with severe asthma who carry an incredibly common genetic variant when they contract a viral illness due to a gene–drug interaction.

Common gene variant reduces effectiveness of pediatric asthma drug

Children with a variant in the SERPINE1 gene – which is found in 60% of the population – may be less responsive to mepolizumab, a drug used to treat asthma flares, according to a study published in the Journal of Allergy and Clinical Immunology.

Children with a common genetic variant may have more inflammation in response to an asthma drug

Children with a variant in the SERPINE1 gene—which is found in 60% of the population—may be less responsive to mepolizumab, a drug used to treat asthma flares, according to a study published in the Journal of Allergy and Clinical Immunology.

Gene Variant Reduced Benefit of Pediatric Asthma Drug

A study indicates pediatric asthma patients with a common gene variant may experience diminished response to mepolizumab during viral infections.